February 2013
- HDC Annual report: what’s happened to our watchdog?
- “Give us Soliris” – lobbying for the world’s most expensive drug
- Abortion numbers declining – ASC’s 2011 Report
March 2013
- The new ethics committees
- NZ patients automatically enrolled in research
- Perinatal hysterectomy rates in NZ AWHC AGM – 11 April 2013
April 2013
- The AllTrials campaign Ben Goldacre in Auckland
- A Sequel to the story of Henrietta Lacks and her cells
- Prevalence of HPV types pre-Gardasil
May 2013
- The Breast Cancer Genes
- PHARMAC consults on its decision not to buy world’s most expensive drug
- Attempt to stop the SOLD trial in New Zealand
- Postnatal Distress Support Network courses
June 2013
- Perinatal & Maternal Mortality in 2011
- Taking back our breast cancer genes
- A Mother and Baby Unit for Auckland
- Breast implants and late diagnosis of breast cancer
July 2013
- Informed consent in the age of targets
- NZ women join lawsuit against mesh “Too much medicine; too little care”
- The Legacy of Cartwright conference – 27 September 2013
August 2013
- Herceptin – shorter beats longer
- National Women’s Annual Clinical Report for 2012
- The Legacy of Cartwright conference – 27 September 2013 HIV/AIDS report for 2012
- Researchers now accessing Guthrie cards without consent
September 2013
- Disciplinary Notes to go on Medical Council website
- The brave new world of NIPT
- The Legacy of Cartwright conference – 27 September 2013
- Attending the first international Preventing Overdiagnosis conference
- Update on Auckland’s Mother and Baby Unit
October 2013
- Essure: Another horrendous contraceptive device
- Spring courses at the Waitakere Women’s Centre
- Preventing Overdiagnosis 2014 conference
- Overdiagnosing and overtreating hypertension
November 2013
- Women’s health service still controversial – whose choice counts?
- Update on Essure
- “Deadly Medicines and Organised Crime” by Peter Gotzsche
- PND Fundraising lunch with Dame Jenny Shipley
December 2013
- Forced caesarean sections for mentally unwell women
- Johnson & Johnson pay $2.2 billion in drug marketing settlement
- Choosing Wisely
- DHB Maternity Quality & Safety reports
